Chimeric Therapeutics Q1 FY26 Financial Report and Clinical Updates
Key points
- Phase 1 study of CHM CDH17 shows promising tumour shrinkage results
- 60% of enrolled patients in CHM CORE-NK trial achieve complete response
- Strategic review initiated to maximize value of Chimeric's assets
- Closing cash of $0.8M at end of June, with additional $2.27M received in July
- Board member Mr. Eric Sullivan retires from the Board
Full summary
Chimeric Therapeutics (ASX: CHM) provided a comprehensive update on its activities for the quarter ended 30 June 2026. The company reported positive interim data from its Phase 1/2 study of CHM CDH17, showing significant tumor shrinkage in patients at Dose Level 3. Additionally, 60% of patients in the CHM CORE-NK trial achieved complete response. Chimeric also initiated a strategic review to explore options for maximizing the value of its assets. The company ended the quarter with $0.8M in cash and received an additional $2.27M in July. The board also saw the retirement of Independent Non-Executive Director Mr. Eric Sullivan.
Outlook
Chimeric Therapeutics anticipates continued clinical progress and expects to complete the CHM CDH17 study later this year, subject to funding. The strategic review aims to unlock additional value for the company.
Summary generated by a large language model. Please interpret with care.